ClinicalTrials.gg
Not yet recruitingNCT07951359Updated Nov 20, 2026

A First-in-human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of BNT3211 in Advanced Solid Tumor, sponsored by BioNTech SE. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by BioNTech SE · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
345
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is the first time BNT3211 will be tested in people. It will evaluate different dose levels of BNT3211 in adults to find suitable doses and to understand how safe the treatment is and how it may help people with advanced solid tumors.

Read the detailed description

This study will consist of two parts (A and B). Part A will be a dose escalation to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BNT3211. Part B will be a dose optimization and proof-of-concept to further investigate the safety, tolerability and preliminarily antitumor activity of BNT3211 at doses selected from Part A. Part B will enroll participants with the same indications as in Part A.

No randomization will be performed in Part A. In Part B, for each selected indication, participants are randomized to the doses selected at the end of Part A using a dynamic allocation procedure.

There will be a screening period, a treatment period, and a follow-up period (including an end-of-treatment visit, a safety follow-up visit, and a survival follow-up period with regular visits).

Participants will receive BNT3211 until disease progression, start of new anticancer treatment, unacceptable toxicity, withdrawal of consent, or until the sponsor terminates the study or any other criterion for discontinuation is met.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Antibody drug conjugates (ADC)
  • Immunotherapy
03

In context

Lead sponsor

BioNTech SE is the lead sponsor of 77 studies on the registry; 25 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Are ≥18 years of age (local laws will be followed if the age of consent is older).
  • Have an performance status of 0 to 1.
  • Have a of ≥3 months in the opinion of the investigator.
  • Have at least one as per v1.1.
  • Have an archival formalin-fixed paraffin-embedded tumor tissue sample available or are willing to be biopsied to obtain a fresh tumor tissue sample.
  • Have or cytologically confirmed locally advanced, recurrent, or solid tumors and must have received all available standard of care (SoC) treatment in accordance with local practice (unless the standard therapy is considered inappropriate or intolerable) and failed at least SoC therapy prior to enrollment.
  • Have an adequate coagulation, hematologic, and organ function as defined by the protocol.
  • (LVEF) ≥50% by either echocardiogram or multi-gated acquisition scan within 28 days prior to first dose of study treatment.

Key Exclusion Criteria:

  • Have had major surgery (not including diagnostic surgery) within the 4 weeks prior to the first dose of study treatment or are planned to undergo major surgery during the course of the study.
  • Have had prior bone marrow transplantation or solid-organ transplantation.
  • Have had an inadequate for prior anticancer treatment or other restricted medications prior to the first dose of medicinal product (IMP) as defined in the protocol.
  • Have received systemic (>10 mg/day of prednisone or its equivalent) or other therapy within 2 weeks prior to the first dose of IMP. Protocol defined exceptions apply.
  • Have received any live or attenuated vaccine within 4 weeks prior to the first dose of IMP or intend to receive a live or attenuated vaccine during the study.
  • Have a history of .
  • Have or spinal cord compression unless asymptomatic or treated and stable off steroids and anticonvulsants for at least 2 weeks prior to the first dose of IMP.
  • Have a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that requires steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Protocol-defined exceptions apply.
  • Have concomitant pulmonary disease, including but not limited to: , restrictive lung disease, lung injury accompanied with disease/connective tissue disorders.
  • Have uncontrolled pleural effusions, ascites, or pericardial effusions that require repeated drainage (once monthly or more frequently).
  • Have active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal conditions that may cause bleeding or perforation in the opinion of the treating investigator.
  • Have an active infection that requires systemic therapy (except for oral antibiotics) within 1 week prior to the first dose of IMP. Participants receiving prophylactic anti-infective therapy (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) may be eligible.
  • Have active or chronic corneal disorders, or other active ocular conditions requiring ongoing therapy, or any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy.
  • Have a known (HIV), virus (HBV), or virus (HCV) infection. Protocol defined exceptions apply.
  • Have any other primary within 3 years prior to the first dose of IMP, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other curatively treated solid tumors.
  • Have unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved according to (US) National Cancer Institute (AEs) Grade ≤1 (unless the investigator determines that certain AEs pose no safety risk to the participant, such as hair loss, Grade 2 peripheral neuropathy or stable hypothyroidism under hormone replacement therapy).
  • Have any of the following heart conditions within 6 months prior to the study treatment:

    • Acute coronary syndrome, coronary artery bypass grafting, congestive heart failure, aortic dissection, stroke, or other Grade 3 and above cardiovascular and cerebrovascular events.
    • functional classification ≥II heart failure or LVEF \<50%.
    • Ventricular arrhythmias requiring clinical intervention, second- to third-degree atrioventricular block, or congenital long syndrome. Participants with treated cardiac arrhythmia/atrial fibrillation are allowed.
    • Mean QT interval corrected by Fridericia's method >450 ms for males or >470 ms for females in three successive screening measurements based on a 12-lead .
  • Unstable thrombotic event (e.g., deep vein thrombosis, arterial thrombosis, pulmonary embolism) requiring therapeutic intervention within 3 months.

Note: Other protocol defined inclusion and exclusion criteria apply.

Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
345 participants (estimated)

Study arms

  • Experimental
    Part A (dose escalation) - BNT3211 monotherapy

    Escalating dose levels of BNT3211.

    Biological: BNT3211

  • Experimental
    Part B (dose optimization) - BNT3211 monotherapy

    Indications as in Part A. Doses will be selected from Part A.

    Biological: BNT3211

Interventions

  • BiologicalBNT3211

    Intravenous infusion

06

What researchers measure

Primary outcomes

  1. Part A only - Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation period

    DLT period defined as the first 21 days. Per dose level.

    Time frame: Up to 21 days from the initiation of first dose of BNT3211

  2. Number of participants with treatment emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEs

    Per dose level (Part A) and per arm (Part B).

    Time frame: From first dose until 35 days after the last dose of BNT3211 (up to 36 months)

  3. Number of participants with dose interruptions, reductions, or discontinuations of study treatment due to TEAEs

    Per dose level (Part A) and per arm (Part B).

    Time frame: From the first until the last dose of BNT3211 (up to 36 months)

  4. Part B only - Objective response rate

    Defined as the proportion of participants with confirmed complete response (CR) or partial response (PR) (per the Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] based on the investigator's assessment) is observed as best overall response. Per arm.

    Time frame: Up to 36 months

Secondary outcomes

  1. PK assessment: Area under the curve (AUC) derived from serum concentrations of BNT3211, total antibody and unconjugated payload

    After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

    Time frame: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

  2. PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT3211, total antibody and unconjugated payload

    After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

    Time frame: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

  3. PK assessment: Time to reach maximum (peak) serum concentration (Tmax) derived from serum concentrations of BNT3211, total antibody and unconjugated payload

    After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

    Time frame: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

  4. PK assessment: Elimination half-life (t1/2) derived from serum concentrations of BNT3211, total antibody and unconjugated payload

    After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

    Time frame: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

  5. Part A only - Objective response rate

    Defined as the proportion of participants with confirmed CR or PR (per RECIST v1.1 based on the investigator's assessment) is observed as best overall response. Per dose level.

    Time frame: Up to 36 months

  6. Disease control rate

    Defined as the proportion of participants in whom a confirmed CR, confirmed PR or stable disease (SD) (per RECIST v1.1 based on the investigator's assessment, SD assessed at least 6 weeks \[±7 days\] after the first BNT3211 dose) is observed as best overall response. Per dose level (Part A) and per arm (Part B).

    Time frame: Up to 36 months

  7. Duration of response

    Defined as the time from first objective response (CR or PR per RECIST v1.1 based on the investigator's assessment) to first occurrence of objective tumor progression (progressive disease per RECIST v1.1 based on the investigator's assessment) or death from any cause, whichever occurs first. Per dose level (Part A) and per arm (Part B).

    Time frame: Up to 36 months

  8. Part B only - Progression free survival

    Defined as the time from first dose of BNT3211 to first objective tumor progression (PD per RECIST 1.1 based on the investigator's assessment), or death from any cause, whichever occurs first. Per arm.

    Time frame: Up to 36 months

  9. Part B only - Overall survival

    Defined as the time from first dose of BNT3211 to death from any cause. Per arm.

    Time frame: Up to 36 months

  10. Anti-drug antibody prevalence

    Defined as proportion of participants who are anti-drug antibody positive (either baseline or post-baseline). Per dose level (Part A) and per arm (Part B). As data permits.

    Time frame: For up to 35 days from the last dose of BNT3211 (up to 36 months)

  11. Anti-drug antibody incidence

    Defined as proportion of participants having treatment-emergent anti-drug antibodies. Per dose level (Part A) and per arm (Part B). As data permits.

    Time frame: For up to approximately 35 days from the last dose of BNT3211 (up to 36 months)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Oct 2029, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Nov 2026
Primary completionEst.
Oct 2029
CompletionEst.
Mar 2030
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951359
Lead sponsor
BioNTech SE
Collaborators
BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Nov 2026 (estimated)
Primary completion
Oct 2029 (estimated)
Completion
Mar 2030 (estimated)
Last update
Nov 20, 2026

Study contacts

BioNTech clinical trials patient information
Contact
patients@biontech.de
+49 6131 9084 ext. 0
BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion